This is three part study that will, in part one assess the safety, tolerability, and PK of a
single dose of CRV431 in healthy volunteers. The second part of the study will be a single
dose drug-drug interaction study in healthy volunteers with CRV431 co-treated with TDF. The
third part of the study will assess the safety, tolerability, PK, and preliminary signal for
antiviral efficacy and identification of clinically-relevant biomarkers of CRV431 with TDF in
stable HBV patients.
Phase:
Phase 1
Details
Lead Sponsor:
ContraVir Pharmaceuticals, Inc. Hepion Pharmaceuticals, Inc.